Lumbar Disc Disease Clinical Trial
Official title:
A Phase 2, Double-Blind, Saline-Controlled, Randomized Study to Evaluate the Safety and Preliminary Efficacy of a Single Dose Intradiscal Injection of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
This is a double-blind, saline-controlled, and randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means.
This is a double-blind, saline-controlled, and randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria will be enrolled. Chronic lumbar disc disease is defined as back and/or radicular pain with degeneration of the disc confirmed by patient history, physical examination, and radiographic measures such as computed tomography (CT), magnetic resonance imaging (MRI), plain film, myelography, discography, or other acceptable means. Subjects randomized to active treatment will undergo bone marrow harvest for processing into BRTX-100 for intradiscal injection. Subjects randomized to control will also undergo a bone marrow and blood harvest but only receive saline intradiscal injection procedures. Subjects will return to the study site for a visit at Week 2, Week 12, Week 26, Week 52 and Week 104/Early Termination. The trial will have a Safety Run-In component that will insert a 3+3 design for the initial subjects dosed with BRTX-100 at 40 × 106 cells. Specifically, the randomization scheme will be briefly shifted from the overall trial 2:1 randomization to an initial 3:1 allotment of intradiscal BRTX-100 versus saline control. As such, four subjects will initially be randomized and administered their agents. There will be a 14 day safety follow-up period that must elapse between dosing of each of the first four (4) subjects. Dosing of each subsequent subject in the Safety Run-In component cannot occur until the independent Medical Monitor (MM) reviews the previously-dosed subject's blinded data, including but not limited to physical examination findings, laboratory values and reported adverse events (AEs) and serious adverse events (SAEs), at the completion of the 14-day visit and documents the findings. If no potential dose- limiting toxicity (DLT) is noted by the MM, the MM will approve the dosing of the next subject. If a potential DLT is noted by the MM, the MM will request that an ad hoc Data Safety Monitoring Board (DSMB) review of unblinded data occur per DSMB Charter before the next subject is dosed. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01941563 -
A Study of SI-6603 in Patients With Lumbar Disc Herniation
|
Phase 3 | |
Completed |
NCT04061759 -
Physiotherapy in Lumbar Disc Pathologies
|
N/A | |
Recruiting |
NCT04727385 -
Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease
|
N/A | |
Completed |
NCT04587401 -
The Effects of Anesthesia on Cerebral Perfusion in Patients With High Blood Pressure
|
N/A | |
Not yet recruiting |
NCT06034041 -
The Effect of Mediclore as an Anti-adhesion Agent and Safety in Full-endoscopic Spine Surgery: a Preliminary Study
|
Phase 4 | |
Recruiting |
NCT04134975 -
Evaluation of the Contribution of Intraoperative Scans Coupled With the Navigation for the Precision of the Positioning of the Pedicle Screws During a Lumbar Spine Surgery: a Prospective Randomised Study
|
N/A | |
Recruiting |
NCT05146583 -
Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease.
|
||
Recruiting |
NCT04641039 -
Postoperative Scar in the Control Excess of Mobility Induced by Annulus Removal on Inserting a Lumbar Disc Prosthesis
|
N/A | |
Completed |
NCT04301232 -
Fast-Track Eligibility and Hospital Discharge for Outpatient Lumbar Discectomy
|
||
Recruiting |
NCT06154005 -
OsteoAdapt SP Advanced Bone Graft Feasibility Study - Transforaminal Interbody Lumbar Fusion
|
Phase 1/Phase 2 | |
Completed |
NCT03977961 -
The Six-Minute Walking Test (6MWT) as a Measure of Functional Impairment in Lumbar Degenerate Disc Disease.
|
||
Enrolling by invitation |
NCT05444751 -
GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries
|
Phase 3 | |
Completed |
NCT02700451 -
Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes
|
N/A | |
Completed |
NCT02421601 -
A Study of SI-6603 in Patients With Lumbar Disc Herniation
|
Phase 3 | |
Active, not recruiting |
NCT03733626 -
Clinical Outcomes Associated With the Use of ViviGen® for the Treatment of Lumbar Degenerative Disc Disease
|
N/A | |
Recruiting |
NCT06462729 -
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
|
Phase 1/Phase 2 | |
Completed |
NCT05345249 -
Erector Spinae Plane Block as Pain Management After Lumbar Fusion Surgery
|
Phase 4 | |
Active, not recruiting |
NCT03060434 -
Pentoxifylline and Lumbar Radiculopathy
|
Phase 4 | |
Withdrawn |
NCT02852187 -
Single Center Study Comparing MOBIS II ST vs MOBIS PEEK
|
N/A | |
Completed |
NCT04062942 -
The Six-Minute Walking Test (6WT) and Timed-Up-and-Go (TUG) Test as Measures of Objective Functional Impairment in Patients Undergoing Interlaminar or Transforaminal Epidural Steroid Injection for Lumbar Degenerative Disc Disease (DDD)
|